WAVEMAN · COMPANY

SCTX · Scribe Therapeutics, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

SCTX

Name: Scribe Therapeutics, Inc. (SCTX) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Scribe Therapeutics, Inc.

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001853921

CLUSTER · 6 INSIDERSACTIVIST 13DC-SUITE BUYING · 2☆ WATCH

INSIDER NET · 180D

$71.3M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-60.8%

XBRL, annual

NET MARGIN

-337.7%

CONVERSIONS · 180D

codes C/M, not in net · no price filed

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$71.3M over 180 days

+$71.3M over 90 days · +$41.3M of it by a 10%+ holder

more than 99% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

fewer than five institutions report holding it

REVENUE

-60.8% year over year (latest quarter)

below 86% of Pharma & Biotech

MARGIN

-337.7% net margin (latest quarter)

below 79% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

6 insiders independently bought a net $71.3M — no planned sales are queued against it.

Avoro Capital Advisors LLC disclosed a 5%+ stake (13.78%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +51.1%

+51.1%12M

INSIDER BUYINSIDER SELL13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

6 insiders reported buying shares.

The record shows a net $71.3M bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Scribe Therapeutics, Inc. insiders bought a net $71.3M of stock across 8 Form 4 purchases and sales, with 6 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Aghazadeh Behzad

Director

BUY

2026-07-28

7,905.0

$144.3K

AH Bio Fund II, L.P.

—

BUY

2026-07-27

333,333.0

$5.0M

GORDON CARL L

Director

BUY

2026-07-27

1,000,000.0

$15.0M

ORBIMED ADVISORS LLC

Director

BUY

2026-07-27

1,000,000.0

$15.0M

Aghazadeh Behzad

Director

BUY

2026-07-24

2,333,333.0

$35.0M

8 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 3 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

5%+ owners

13D = intent to influence · 13G = passive

Avoro Capital Advisors LLC

ACTIVIST 13D · 2026-07-30

13.78%

Avoro Ventures LLC

ACTIVIST 13D · 2026-07-30

2.6%

Aghazadeh Behzad

ACTIVIST 13D · 2026-07-30

16.37%

ELI LILLY & Co

ACTIVIST 13D · 2026-07-30

7.3%

ORBIMED ADVISORS LLC

ACTIVIST 13D · 2026-07-29

7.2%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.